Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $32.9 million.

  • GeneDx Holdings' Other Accumulated Expenses rose 99.13% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 99.13%. This contributed to the annual value of $20.5 million for FY2024, which is 25.48% up from last year.
  • Per GeneDx Holdings' latest filing, its Other Accumulated Expenses stood at $32.9 million for Q3 2025, which was up 72.18% from $19.1 million recorded in Q2 2025.
  • GeneDx Holdings' Other Accumulated Expenses' 5-year high stood at $81.6 million during Q2 2022, with a 5-year trough of $11.1 million in Q2 2024.
  • For the 3-year period, GeneDx Holdings' Other Accumulated Expenses averaged around $21.4 million, with its median value being $19.9 million (2023).
  • In the last 5 years, GeneDx Holdings' Other Accumulated Expenses surged by 229.59% in 2022 and then slumped by 75.60% in 2023.
  • Over the past 5 years, GeneDx Holdings' Other Accumulated Expenses (Quarterly) stood at $33.4 million in 2021, then soared by 48.88% to $49.7 million in 2022, then slumped by 67.13% to $16.3 million in 2023, then grew by 25.48% to $20.5 million in 2024, then surged by 99.13% to $32.9 million in 2025.
  • Its Other Accumulated Expenses stands at $32.9 million for Q3 2025, versus $19.1 million for Q2 2025 and $24.6 million for Q1 2025.